InfuSystem Holdings Inc (NYSEAMERICAN:INFU) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 19,900 shares, a decrease of 32.1% from the September 30th total of 29,300 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 38,700 shares, the days-to-cover ratio is presently 0.5 days.
Shares of NYSEAMERICAN:INFU opened at $7.66 on Thursday. InfuSystem has a 12-month low of $3.30 and a 12-month high of $8.12.
InfuSystem (NYSEAMERICAN:INFU) last announced its quarterly earnings data on Wednesday, August 14th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $19.72 million for the quarter.
Several large investors have recently made changes to their positions in the stock. Gabelli Funds LLC boosted its stake in InfuSystem by 4.3% in the 3rd quarter. Gabelli Funds LLC now owns 360,000 shares of the medical instruments supplier’s stock worth $1,904,000 after purchasing an additional 15,000 shares during the period. White Pine Capital LLC boosted its stake in InfuSystem by 23.3% in the 2nd quarter. White Pine Capital LLC now owns 494,670 shares of the medical instruments supplier’s stock worth $2,127,000 after purchasing an additional 93,420 shares during the period. Finally, AWM Investment Company Inc. boosted its stake in InfuSystem by 9.1% in the 2nd quarter. AWM Investment Company Inc. now owns 1,855,362 shares of the medical instruments supplier’s stock worth $7,978,000 after purchasing an additional 155,092 shares during the period.
InfuSystem Company Profile
InfuSystem Holdings Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Recommended Story: Front-End Load
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.